ASSESSING CONGESTIVE HEART RISK IN PATIENTS TREATED OR POTENTIALLY TO BE TREATED WITH A PEROXISOME-PROLIFERATOR-ACTIVATOR-RECEPTOR-GAMMA AGONIST OR A THIAZOLIDINEDIONE
摘要
<p>Methods are provided for assessing a patient being treated with a peroxisome - proliferator-activator-receptor-? (PPAR-?) agonist or a thiazolidinedione (TZD), or having a condition treatable with a peroxisome-proliferator-activator-receptor-? agonist or a thiazolidinedione. Methods include measuring a galectin-3 concentration or a change in a galectin-3 concentration in a body fluid of a patient being treated with a peroxisome-proliferator-activator-receptor-? agonist or a thiazolidinedione. A comparison to galectin-3 levels or changes in comparable patients provides information indicative of congestive heart risk.</p>